Tenpoint Therapeutics has launched a national campaign for YUVEZZI, a prescription eye drop approved for presbyopia.
Background
Presbyopia is a common age-related condition that typically begins around age 45, affecting approximately 128 million adults in the US and about 2 billion people globally. It can interfere with daily activities such as reading and using digital devices. YUVEZZI is a dual-agent ophthalmic solution approved for managing this condition.
Data Highlights
YUVEZZI (carbachol and brimonidine tartrate) is approved for adults with presbyopia and has shown efficacy in clinical studies, providing up to eight continuous hours of improved close-up vision.
Key Findings
YUVEZZI is the first dual-agent eye drop approved for presbyopia treatment.
Clinical studies demonstrated responder rates of 19.4% to 38.2% at various time points compared to vehicle controls.
Common side effects include headache, impaired vision, and temporary eye pain.
Clinical Implications
Healthcare professionals should be aware of YUVEZZI as a treatment option for presbyopia and consider discussing its benefits and potential side effects with patients.
Conclusion
The launch of the YUVEZZI campaign is intended to raise awareness about presbyopia.
Often, these patients are unhappy with this reality check of aging and do not want to wear reading glasses, which is why practitioners and industry are always looking for ways to help. The challenge is to develop therapies that correct presbyopia while maintaining the emmetrope’s clear distance vision.
An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.
